Cargando…
EPIC: an effective low toxicity regimen for relapsing lymphoma.
We have treated 40 patients was relapsed or resistant lymphoma with the combination of Etoposide, Prednisolone, Ifosfamide and Cisplatin (EPIC). Complete response was obtained in 11 patients (28%) with an overall response of 58%. The presence of bulky disease (P < 0.005), elevated LDH serum level...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968387/ https://www.ncbi.nlm.nih.gov/pubmed/8353050 |
_version_ | 1782134729181495296 |
---|---|
author | Hickish, T. Roldan, A. Cunningham, D. Mansi, J. Ashley, S. Nicolson, V. Gore, M. E. Catovsky, D. Smith, I. E. |
author_facet | Hickish, T. Roldan, A. Cunningham, D. Mansi, J. Ashley, S. Nicolson, V. Gore, M. E. Catovsky, D. Smith, I. E. |
author_sort | Hickish, T. |
collection | PubMed |
description | We have treated 40 patients was relapsed or resistant lymphoma with the combination of Etoposide, Prednisolone, Ifosfamide and Cisplatin (EPIC). Complete response was obtained in 11 patients (28%) with an overall response of 58%. The presence of bulky disease (P < 0.005), elevated LDH serum levels (P < 0.005), response to prior chemotherapy (P < 0.01) and B symptoms (P < 0.005) were significantly associated with response. However on multivariate analysis only the presence of bulky disease and of B symptoms were independent adverse factors for response and for survival. The regimen was well tolerated with myelosuppression being the most common toxicity. Leucopenia < or 1,000 microliters-1 and thrombocytopenia < or = 25,000 microliters-1 developed in 27% and 4% of cycles respectively. There were no treatment related deaths. The EPIC regimen has equivalent activity to other reported cisplatin based regimens used in the treatment of recurrent lymphoma, but is associated with lower treatment related morbidity and mortality. |
format | Text |
id | pubmed-1968387 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1993 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-19683872009-09-10 EPIC: an effective low toxicity regimen for relapsing lymphoma. Hickish, T. Roldan, A. Cunningham, D. Mansi, J. Ashley, S. Nicolson, V. Gore, M. E. Catovsky, D. Smith, I. E. Br J Cancer Research Article We have treated 40 patients was relapsed or resistant lymphoma with the combination of Etoposide, Prednisolone, Ifosfamide and Cisplatin (EPIC). Complete response was obtained in 11 patients (28%) with an overall response of 58%. The presence of bulky disease (P < 0.005), elevated LDH serum levels (P < 0.005), response to prior chemotherapy (P < 0.01) and B symptoms (P < 0.005) were significantly associated with response. However on multivariate analysis only the presence of bulky disease and of B symptoms were independent adverse factors for response and for survival. The regimen was well tolerated with myelosuppression being the most common toxicity. Leucopenia < or 1,000 microliters-1 and thrombocytopenia < or = 25,000 microliters-1 developed in 27% and 4% of cycles respectively. There were no treatment related deaths. The EPIC regimen has equivalent activity to other reported cisplatin based regimens used in the treatment of recurrent lymphoma, but is associated with lower treatment related morbidity and mortality. Nature Publishing Group 1993-09 /pmc/articles/PMC1968387/ /pubmed/8353050 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Hickish, T. Roldan, A. Cunningham, D. Mansi, J. Ashley, S. Nicolson, V. Gore, M. E. Catovsky, D. Smith, I. E. EPIC: an effective low toxicity regimen for relapsing lymphoma. |
title | EPIC: an effective low toxicity regimen for relapsing lymphoma. |
title_full | EPIC: an effective low toxicity regimen for relapsing lymphoma. |
title_fullStr | EPIC: an effective low toxicity regimen for relapsing lymphoma. |
title_full_unstemmed | EPIC: an effective low toxicity regimen for relapsing lymphoma. |
title_short | EPIC: an effective low toxicity regimen for relapsing lymphoma. |
title_sort | epic: an effective low toxicity regimen for relapsing lymphoma. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968387/ https://www.ncbi.nlm.nih.gov/pubmed/8353050 |
work_keys_str_mv | AT hickisht epicaneffectivelowtoxicityregimenforrelapsinglymphoma AT roldana epicaneffectivelowtoxicityregimenforrelapsinglymphoma AT cunninghamd epicaneffectivelowtoxicityregimenforrelapsinglymphoma AT mansij epicaneffectivelowtoxicityregimenforrelapsinglymphoma AT ashleys epicaneffectivelowtoxicityregimenforrelapsinglymphoma AT nicolsonv epicaneffectivelowtoxicityregimenforrelapsinglymphoma AT goreme epicaneffectivelowtoxicityregimenforrelapsinglymphoma AT catovskyd epicaneffectivelowtoxicityregimenforrelapsinglymphoma AT smithie epicaneffectivelowtoxicityregimenforrelapsinglymphoma |